Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia

Akihiro Iguchi, Yuko Cho, Minako Sugiyama, Yukayo Terashita, Tadashi Ariga, Yosuke Hosoya, Shinsuke Hirabayashi, Atsushi Manabe, Keisuke Hara, Tetsuya Aiba, Tsugumi Shiokawa, Hiroko Tada, Norihiro Sato

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Bortezomib has been shown to be effective and well-tolerated in patients with refractory acute lymphoblastic leukemia (ALL) in the Therapeutic Advances in Childhood Leukemia trial. However, the safety and efficacy of bortezomib have not been evaluated in Japanese pediatric patients. Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL. A total of six patients with B-precursor ALL were enrolled in this study. Four-dose bortezomib (1.3 mg/m2/dose) combined with two standard induction chemotherapies was used. Prolonged pancytopenia (grade 4) was observed in all patients. Four of the six patients developed severe infectious complications. Peripheral neuropathy (grade 2) occurred in five patients. The individual plasma bortezomib concentration–time profiles were not related to toxicity and efficacy. Five patients were evaluable for response, and four patients achieved complete response (CR) or CR without platelet recovery (80%). In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL. Attention must be given to severe infectious complications when performing re-induction chemotherapy including bortezomib.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalInternational Journal of Hematology
DOIs
Publication statusAccepted/In press - Apr 11 2017

Fingerprint

Induction Chemotherapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Safety
Bortezomib
Pancytopenia
Peripheral Nervous System Diseases
Neutropenia
Leukemia
Blood Platelets
Clinical Trials

Keywords

  • Acute pediatric lymphoblastic leukemia
  • Bortezomib
  • Infectious complication
  • Japanese

ASJC Scopus subject areas

  • Hematology

Cite this

Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia. / Iguchi, Akihiro; Cho, Yuko; Sugiyama, Minako; Terashita, Yukayo; Ariga, Tadashi; Hosoya, Yosuke; Hirabayashi, Shinsuke; Manabe, Atsushi; Hara, Keisuke; Aiba, Tetsuya; Shiokawa, Tsugumi; Tada, Hiroko; Sato, Norihiro.

In: International Journal of Hematology, 11.04.2017, p. 1-8.

Research output: Contribution to journalArticle

Iguchi, A, Cho, Y, Sugiyama, M, Terashita, Y, Ariga, T, Hosoya, Y, Hirabayashi, S, Manabe, A, Hara, K, Aiba, T, Shiokawa, T, Tada, H & Sato, N 2017, 'Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia', International Journal of Hematology, pp. 1-8. https://doi.org/10.1007/s12185-017-2235-z
Iguchi, Akihiro ; Cho, Yuko ; Sugiyama, Minako ; Terashita, Yukayo ; Ariga, Tadashi ; Hosoya, Yosuke ; Hirabayashi, Shinsuke ; Manabe, Atsushi ; Hara, Keisuke ; Aiba, Tetsuya ; Shiokawa, Tsugumi ; Tada, Hiroko ; Sato, Norihiro. / Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia. In: International Journal of Hematology. 2017 ; pp. 1-8.
@article{8e2e7747bf3541ba975e6cd5c05ba94f,
title = "Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia",
abstract = "Bortezomib has been shown to be effective and well-tolerated in patients with refractory acute lymphoblastic leukemia (ALL) in the Therapeutic Advances in Childhood Leukemia trial. However, the safety and efficacy of bortezomib have not been evaluated in Japanese pediatric patients. Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL. A total of six patients with B-precursor ALL were enrolled in this study. Four-dose bortezomib (1.3 mg/m2/dose) combined with two standard induction chemotherapies was used. Prolonged pancytopenia (grade 4) was observed in all patients. Four of the six patients developed severe infectious complications. Peripheral neuropathy (grade 2) occurred in five patients. The individual plasma bortezomib concentration–time profiles were not related to toxicity and efficacy. Five patients were evaluable for response, and four patients achieved complete response (CR) or CR without platelet recovery (80{\%}). In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL. Attention must be given to severe infectious complications when performing re-induction chemotherapy including bortezomib.",
keywords = "Acute pediatric lymphoblastic leukemia, Bortezomib, Infectious complication, Japanese",
author = "Akihiro Iguchi and Yuko Cho and Minako Sugiyama and Yukayo Terashita and Tadashi Ariga and Yosuke Hosoya and Shinsuke Hirabayashi and Atsushi Manabe and Keisuke Hara and Tetsuya Aiba and Tsugumi Shiokawa and Hiroko Tada and Norihiro Sato",
year = "2017",
month = "4",
day = "11",
doi = "10.1007/s12185-017-2235-z",
language = "English",
pages = "1--8",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia

AU - Iguchi, Akihiro

AU - Cho, Yuko

AU - Sugiyama, Minako

AU - Terashita, Yukayo

AU - Ariga, Tadashi

AU - Hosoya, Yosuke

AU - Hirabayashi, Shinsuke

AU - Manabe, Atsushi

AU - Hara, Keisuke

AU - Aiba, Tetsuya

AU - Shiokawa, Tsugumi

AU - Tada, Hiroko

AU - Sato, Norihiro

PY - 2017/4/11

Y1 - 2017/4/11

N2 - Bortezomib has been shown to be effective and well-tolerated in patients with refractory acute lymphoblastic leukemia (ALL) in the Therapeutic Advances in Childhood Leukemia trial. However, the safety and efficacy of bortezomib have not been evaluated in Japanese pediatric patients. Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL. A total of six patients with B-precursor ALL were enrolled in this study. Four-dose bortezomib (1.3 mg/m2/dose) combined with two standard induction chemotherapies was used. Prolonged pancytopenia (grade 4) was observed in all patients. Four of the six patients developed severe infectious complications. Peripheral neuropathy (grade 2) occurred in five patients. The individual plasma bortezomib concentration–time profiles were not related to toxicity and efficacy. Five patients were evaluable for response, and four patients achieved complete response (CR) or CR without platelet recovery (80%). In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL. Attention must be given to severe infectious complications when performing re-induction chemotherapy including bortezomib.

AB - Bortezomib has been shown to be effective and well-tolerated in patients with refractory acute lymphoblastic leukemia (ALL) in the Therapeutic Advances in Childhood Leukemia trial. However, the safety and efficacy of bortezomib have not been evaluated in Japanese pediatric patients. Here, we report the results of a clinical trial designed to evaluate the safety of bortezomib combined with induction chemotherapy in Japanese children with refractory ALL. A total of six patients with B-precursor ALL were enrolled in this study. Four-dose bortezomib (1.3 mg/m2/dose) combined with two standard induction chemotherapies was used. Prolonged pancytopenia (grade 4) was observed in all patients. Four of the six patients developed severe infectious complications. Peripheral neuropathy (grade 2) occurred in five patients. The individual plasma bortezomib concentration–time profiles were not related to toxicity and efficacy. Five patients were evaluable for response, and four patients achieved complete response (CR) or CR without platelet recovery (80%). In conclusion, four-dose bortezomib (1.3 mg/m2/dose) combined with standard re-induction chemotherapy was associated with a high risk of infectious complications induced by prolonged neutropenia, although high efficacy has been achieved for Japanese pediatric patients with refractory ALL. Attention must be given to severe infectious complications when performing re-induction chemotherapy including bortezomib.

KW - Acute pediatric lymphoblastic leukemia

KW - Bortezomib

KW - Infectious complication

KW - Japanese

UR - http://www.scopus.com/inward/record.url?scp=85017438948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017438948&partnerID=8YFLogxK

U2 - 10.1007/s12185-017-2235-z

DO - 10.1007/s12185-017-2235-z

M3 - Article

C2 - 28401497

AN - SCOPUS:85017438948

SP - 1

EP - 8

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

ER -